Transaction · 0001104659-26-105119
APGEApogee Therapeutics, Inc.
Fairmount Funds Management LLC
Fairmount Funds Management LLC, DIR, reported a transaction classified as return at Apogee Therapeutics, Inc. involving 47758.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
returnSEC transaction code DDIR
- Trade date
- Sep 03, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingmissing priceThe filing did not provide a usable price per share.
APGE price since this filing
Daily closing prices, with the filing date and available return windowsAPGE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.7%1w ago -0.1%1d ago +0.0%
Returns since7d30d90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- return Code D
- Identifier
- 0001104659-26-105119 Stock Option (Right to Buy)
- Transaction date
- Sep 03, 2026 Filed Sep 03, 2026, 09:30 PM · 0d delay
- Shares
- 47,758 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 0 sh Indirect · By Tomas Kiselak
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction
Filing-only score
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
Low filing signal
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
Missing facts
Read the scoring methodology- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
No officer title
Officer NoDirector Yes10% NoOther No
Footnotes & amended
- F1
Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"),…
- F2
Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr…
- F3
The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the opti…
- F4
As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly o…
- F5
Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option…
- F6
Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obliga…
Related transactions
Same SEC filing0 other transactions
Recent company activity
APGE0 recent txs